Exclusive Summary

• Losartan Potassium's original patent has long expired, making it a mature and competitive global generic market with stable demand and profit potential.
• Hypertension is a widespread global disease with a huge and growing patient base, ensuring substantial and consistent market demand for Losartan Potassium as a first-line treatment.
• The product's US FDA GMP certification and registration in the US demonstrate top-tier international quality, facilitating access to major regulated global markets.
• Losartan Potassium offers significant cost advantages over the originator drug, meeting the global healthcare system's need for affordable and effective medications, thus improving accessibility.
• Losartan Potassium is a WHO essential medicine and widely recommended as a first-line treatment for hypertension, backed by extensive clinical evidence and high recognition.